Medtronic Posts 7 Percent Growth in Q1
(NYSE:MDT), a global medical technology leader specializing in cardiovascular, neuroscience, and surgical devices, reported Q1 FY2026 earnings on August 19, 2025. The most notable news from the release was a strong beat on both profits and revenue: Non-GAAP earnings per share reached $1.26, compared to estimates of $1.23, while Non-GAAP revenue hit $8.54 billion, $160 million above expectations. The company also raised its full-year FY26 non-GAAP EPS outlook, supported by solid revenue growth in its Cardiovascular and Diabetes segments. Overall, The quarter showed continued operational momentum, but also revealed ongoing margin pressures and a major portfolio move with the planned spin-off of the Diabetes business.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q4 2025 earnings report.
Medtronic develops and manufactures a wide range of medical devices, including implantable cardiac pacemakers, heart valves, neurostimulation systems, insulin pumps, and surgical robotics platforms. It serves hospitals, clinics, and doctors—reaching over 150 countries worldwide.
Source Fool.com
Medtronic plc Stock
We see a rather positive sentiment for Medtronic plc with 20 Buy predictions and 1 Sell predictions.
With a target price of 89 € there is a slightly positive potential of 5.46% for Medtronic plc compared to the current price of 84.39 €.
